Suppr超能文献

铰链环突变可用于控制人半胱氨酸蛋白酶抑制剂 C 的 3D 结构域交换和淀粉样变性。

Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C.

机构信息

Department of Medicinal Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland.

出版信息

J Struct Biol. 2011 Feb;173(2):406-13. doi: 10.1016/j.jsb.2010.11.009. Epub 2010 Nov 11.

Abstract

Cystatins are natural inhibitors of cysteine proteases, enzymes that are widely distributed in animals, plants, and microorganisms. Human cystatin C (hCC) has been also recognized as an aggregating protein directly involved in the formation of pathological amyloid fibrils, and these amyloidogenic properties greatly increase in a naturally occurring L68Q hCC variant. For a long time only dimeric structure of wild-type hCC has been known. The dimer is created through 3D domain swapping process, in which two parts of the cystatin structure become separated from each other and next exchanged between two molecules. Important role in the domain swapping plays the L1 loop, which connects the exchanging segments and, upon dimerization, transforms from a β-turn into a part of a long β-strand. In the very recently published first monomeric structure of human cystatin C (hCC-stab1), dimerization was abrogated due to clasping of the β-strands from the swapping domains by an engineered disulfide bridge. We have designed and constructed another mutated cystatin C with the smallest possible structural intervention, that is a single-point mutation replacing hydrophobic V57 from the L1 loop by polar asparagine, known as a stabilizer of a β-turn motif. V57N hCC mutant occurred to be stable in its monomeric form and crystallized as a monomer, revealing typical cystatin fold with a five-stranded antiparallel β-sheet wrapped around an α-helix. Here we report a 2.04 Å resolution crystal structure of V57N hCC and discuss the architecture of the protein in comparison to chicken cystatin, hCC-stab1 and dimeric hCC.

摘要

半胱氨酸蛋白酶抑制剂是一类广泛存在于动物、植物和微生物中的半胱氨酸蛋白酶天然抑制剂。人胱抑素 C(hCC)也被认为是一种直接参与病理性淀粉样纤维形成的聚集蛋白,并且这些淀粉样形成特性在天然存在的 L68Q hCC 变体中大大增加。长期以来,人们只知道野生型 hCC 的二聚体结构。二聚体是通过 3D 结构域交换过程形成的,其中胱抑素结构的两部分彼此分离,然后在两个分子之间交换。L1 环在结构域交换中起着重要作用,它连接着交换的片段,并且在二聚化时,从β-转角转变为长β-链的一部分。在最近发表的第一篇人胱抑素 C(hCC-stab1)单体结构中,由于工程化的二硫键使交换结构域的β-链扣紧,二聚化被废除。我们设计并构建了另一种突变胱抑素 C,结构干预最小,即通过单点突变将 L1 环中的疏水性 V57 替换为极性天冬酰胺,天冬酰胺已知可稳定β-转角基序。V57N hCC 突变体以单体形式稳定存在,并结晶为单体,显示出典型的胱抑素折叠,由五股反平行β-折叠围绕一个α-螺旋包裹。在这里,我们报告了 V57N hCC 的 2.04 Å分辨率晶体结构,并讨论了与鸡胱抑素、hCC-stab1 和二聚体 hCC 相比,该蛋白质的结构。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验